Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > So I'm in for
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by TraderBenon Mar 16, 2017 8:43am
164 Views
Post# 25986728

RE:RE:RE:RE:So I'm in for

RE:RE:RE:RE:So I'm in for
suitman87 wrote: I got it from comparisons of similar comapnies in similar fiscal situations. I think we are on a ship that isn't moving very quickly but its moving and we are fixing the engine. Will be pateint even if it takes years. i don't care about time.


There is no company (other than Valeant) that is leveraged like Concordia with the same business model of stuffing the channel.  And you won't have to be "pateint" for long...

We note that Concordia will have ~$270MM in interest payments, $40MM in amortization payments, and principal repayment of $34MM (Oct/17) this year. In combination with the ~ $100MM Feb/17 earn-out, we anticipate these expenses will consume Concordia's FCF. Details of our forecast revisions are in Exhibit 2. 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities